To include your compound in the COVID-19 Resource Center, submit it here.

Medivir reports interim ASPIRE data

Medivir AB (SSE:MVIR B) reported interim 48-week data from the Phase IIb ASPIRE (C206) trial of TMC435 in 462

Read the full 190 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE